URMC Research Network - Charles Sparks

Find People

Charles Sparks

Title	Professor Emeritus
Institution	School of Medicine and Dentistry
Department	Pathology and Laboratory Medicine
Address	University of Rochester Medical Center School of Medicine and Dentistry 601 Elmwood Ave, Box 608 Rochester NY 14642

Awards And Honors

1974	-	1975	Chief Resident in Pathology, University of Pennsylvania
1975	-	1977	Individual Research Service Award Grantee, National Institutes of Health
1978	-	2004	Conferee. Lipid Metabolism and Atherosclerosis, 1978, '79, '80, '81, '84, '86, '88, '90, '92, '96, '00, '04 Gordon Research Conference, Kimball Union Academy, Meriden, NH
1981			Invited Speaker. Gordon Research Conference on Atherosclerosis: "Is intestinal apo B a determinant for lipoprotein recognition?"
1988			Co-Chair. National Symposium Meeting, American Diabetes Association, Lipoproteins, Diabetes and Atherosclerosis.
1998			Co-Chair. Thrombogenic Factors and Recurrent Coronary Events Symposium, Perugia, Italy
2002	-	2005	Secretarial Appointee. Department of Veterans Affairs Medical Research Service Merit Review Subcommittee for Endocrinology (Chair: Endocrinology-A Review Board, Fall 2003, Spring & Fall 2004)

Overview

Apo B exists as B48 and B100 produced through a novel posttranscriptive mechanism of apo B mRNA editing producing protein products of differing size with differing metabolisms. The goal of our research is to understand apo B triglyceride-rich lipoprotein (TRL) assembly contrasting B100 and B48 synthetic pathways. McArdle RH-7777 cells (McA) have provided many useful insights into inherent differences in B100 and B48 in TRL biogenesis. Recent studies indicate that B100-TRL assembly occurs by lipidation of conformationally "acceptable" B100. B48 undergoes initial lipidation similar to B100 followed by neutral lipidation of the precursor high density lipoprotein particle (B48-HDL) to form B48-TRL. More than 70% of the triglyceride (TG) fatty acids (FA) arise from cytosolic, stored TG through a process involving lipolysis/reesterification. Lipolyzed FAs, possibly through acylation reactions with PL intermediates, traverse the ER membrane by unknown means prior to fusion with B48-HDL. Unlike B100, that is synthesized and rapidly secreted by rat hepatocytes (RH), there is a kinetically distinct pool of B48 that has a long cellular retention time. We hypothesize that this pool may provide a ready supply of B48-HDL as a precursor for the rapid assembly of TRL via a later assembly step. In cells that make predominantly B48, such as intestine, the cellular pool of B48 allows TRL secretion to occur without a requirement for de novo apo B synthesis. We recently identified a novel protein factor, an apo B secretion enhancer (BSE), whose expression correlates with apo B mRNA abundance in McA cells transfected with BSE. Apo B mRNA abundance, however, does not correspond with a proportional increase in apo B secretion. Studies explore the role of BSE in the observed changes in apo B mRNA stability/transcription. Apo B degradation studies address the non-proportional secretory rate. A phospholipid (PL)-dependent pathway for the stimulation of apo B secretion by BSE is suggested as BSE is homologous with betaine homocysteine methyltransferase (BHMT), a methylation enzyme. An hypothesis explored is that, apart from its ability to stabilize apo B mRNA, an ER form of BSE may provide newly synthesized phosphatidylcholine (PC) via phosphatidylethanolamine (PE) methylation of phosphatidylserine (PS) and increased supply of PL may be a mechanism for the enhancing secretion of apo B.

Importance of the research is related to the role of apo B in lipid transport and as a factor associated with risk of arterial disease. Additional research focuses on the role of apo B as a risk factor in developing heart attacks, strokes, and in recurrent heart attacks in human populations.

Selected Publications

Chamberlain JM, O'Dell C, Sparks CE, Sparks JD. Insulin suppression of apolipoprotein B in McArdle RH7777 cells involves increased sortilin 1 interaction and lysosomal targeting. Biochem Biophys Res Commun. 2013 Jan 4; 430(1):66-71.

View in: PubMed
Le NT, Corsetti JP, Dehoff-Sparks JL, Sparks CE, Fujiwara K, Abe J. Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation. Int J Inflam. 2012; 2012:678190.

View in: PubMed
Sparks CE, Sparks JD. Hepatic steatosis and VLDL hypersecretion. Curr Opin Lipidol. 2012 Aug; 23(4):395-7.

View in: PubMed
Sparks JD, Sparks CE, Adeli K. Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2012 Sep; 32(9):2104-12.

View in: PubMed
Corsetti JP, Bakker SJ, Sparks CE, Dullaart RP. Apolipoprotein A-II Influences Apolipoprotein E-Linked Cardiovascular Disease Risk in Women with High Levels of HDL Cholesterol and C-Reactive Protein. PLoS One. 2012; 7(6):e39110.

View in: PubMed
Corsetti JP, Gansevoort RT, Bakker SJ, Navis G, Sparks CE, Dullaart RP. Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein. Metabolism. 2012 Jul; 61(7):996-1002.

View in: PubMed
Corsetti JP, Ryan D, Moss AJ, McCarthy J, Goldenberg I, Zareba W, Sparks CE. Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels. Thromb Haemost. 2011 Nov 30; 106(6):1170-8.

View in: PubMed
Sparks JD, Chamberlain JM, O'Dell C, Khatun I, Hussain MM, Sparks CE. Acute suppression of apo B secretion by insulin occurs independently of MTP. Biochem Biophys Res Commun. 2011 Mar 11; 406(2):252-6.

View in: PubMed
Corsetti JP, Gansevoort RT, Navis G, Sparks CE, Dullaart RP. LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP. Atherosclerosis. 2011 Feb; 214(2):373-6.

View in: PubMed
Sparks JD, Cianci J, Jokinen J, Chen LS, Sparks CE. Interleukin-6 mediates hepatic hypersecretion of apolipoprotein B. Am J Physiol Gastrointest Liver Physiol. 2010 Oct; 299(4):G980-9.

View in: PubMed
Sparks CE, Sparks JD. Lipid metabolism: insights into the complexity of VLDL metabolic pathways. Curr Opin Lipidol. 2010 Jun; 21(3):280-1.

View in: PubMed
Corsetti JP, Ryan D, Rainwater DL, Moss AJ, Zareba W, Sparks CE. Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels. Arterioscler Thromb Vasc Biol. 2010 Aug; 30(8):1657-64.

View in: PubMed
Corsetti JP, Gansevoort RT, Sparks CE, Dullaart RP. Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest. 2010 Jun; 40(6):483-9.

View in: PubMed
Corsetti JP, Ryan D, Rainwater DL, Moss AJ, Zareba W, Block RC, Sparks CE. Lp(a) and risk of recurrent cardiac events in obese postinfarction patients. Obesity (Silver Spring). 2008 Dec; 16(12):2717-22.

View in: PubMed
Sparks JD, Sparks CE. Overindulgence and metabolic syndrome: is FoxO1 a missing link? J Clin Invest. 2008 Jun; 118(6):2012-5.

View in: PubMed
Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE. Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):548-54.

View in: PubMed
Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE. Glycoprotein Ibalpha polymorphism T145M, elevated lipoprotein-associated phospholipase A2, and hypertriglyceridemia predict risk for recurrent coronary events in diabetic postinfarction patients. Diabetes. 2007 May; 56(5):1429-35.

View in: PubMed
Corsetti JP, Ryan D, Moss AJ, Zareba W, Sparks CE. NAD(P)H oxidase polymorphism (C242T) and high HDL cholesterol associate with recurrent coronary events in postinfarction patients. Atherosclerosis. 2008 Jan; 196(1):461-8.

View in: PubMed
Chirieac DV, Davidson NO, Sparks CE, Sparks JD. PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice. Am J Physiol Gastrointest Liver Physiol. 2006 Sep; 291(3):G382-8.

View in: PubMed
Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem. 2006 Jul; 52(7):1331-8.

View in: PubMed
Sparks JD, Collins HL, Chirieac DV, Cianci J, Jokinen J, Sowden MP, Galloway CA, Sparks CE. Hepatic very-low-density lipoprotein and apolipoprotein B production are increased following in vivo induction of betaine-homocysteine S-methyltransferase. Biochem J. 2006 Apr 15; 395(2):363-71.

View in: PubMed
Corsetti JP, Zareba W, Moss AJ, Rainwater DL, Sparks CE. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis. 2006 Jul; 187(1):191-7.

View in: PubMed
Moss AJ, Ryan D, Oakes D, Goldstein RE, Greenberg H, Bodenheimer MM, Brown MW, Case RB, Dwyer EM, Eberly SW, Francis CW, Gillespie JA, Krone RJ, Lichstein E, MacCluer JW, Marcus FI, McCarthy J, Sparks CE, Zareba W. Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction. Am J Cardiol. 2005 Jul 15; 96(2):177-82.

View in: PubMed
Corsetti JP, Zareba W, Moss AJ, Sparks CE. Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients. Atherosclerosis. 2005 Dec; 183(2):293-300.

View in: PubMed
Corsetti JP, Zareba W, Moss AJ, Sparks CE. Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis. 2004 Dec; 177(2):367-73.

View in: PubMed
Chirieac DV, Collins HL, Cianci J, Sparks JD, Sparks CE. Altered triglyceride-rich lipoprotein production in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab. 2004 Jul; 287(1):E42-9.

View in: PubMed
Corsetti JP, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rainwater DL, Sparks CE. Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients. Atherosclerosis. 2003 Dec; 171(2):351-8.

View in: PubMed
Fadl YY, Zareba W, Moss AJ, Marder VJ, Sparks CS, Miller Watelet LF, Carroll ER. History of hypertension and enhanced thrombogenic activity in postinfarction patients. Hypertension. 2003 Apr; 41(4):943-9.

View in: PubMed
Chirieac DV, Cianci J, Collins HL, Sparks JD, Sparks CE. Insulin suppression of VLDL apo B secretion is not mediated by the LDL receptor. Biochem Biophys Res Commun. 2002 Sep 13; 297(1):134-7.

View in: PubMed
Harb TS, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rifai N, Miller Watelet LF, Arora R, Brown MW, Case RB, Dwyer EM, Gillespie JA, Goldstein RE, Greenberg H, Hochman J, Krone RJ, Liang CS, Lichstein E, Little W, Marcus FI, Oakes D, Sparks CE, VanVoorhees L. Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol. 2002 Jan 15; 89(2):216-21.

View in: PubMed
Zareba W, Pancio G, Moss AJ, Kalaria VG, Marder VJ, Weiss HJ, Watelet LF, Sparks CE. Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators. Thromb Haemost. 2001 Sep; 86(3):791-9.

View in: PubMed
Chirieac DV, Chirieac LR, Corsetti JP, Cianci J, Sparks CE, Sparks JD. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Physiol Endocrinol Metab. 2000 Nov; 279(5):E1003-11.

View in: PubMed
Sparks JD, Shaw WN, Corsetti JP, Bolognino M, Pesek JF, Sparks CE. Insulin-treated Zucker diabetic fatty rats retain the hypertriglyceridemia associated with obesity. Metabolism. 2000 Nov; 49(11):1424-30.

View in: PubMed
Fisher SD, Zareba W, Moss AJ, Marder VJ, Sparks CE, Hochman J, Liang C, Krone RJ. Effect of smoking on lipid and thrombogenic factors two months after acute myocardial infarction. Am J Cardiol. 2000 Oct 15; 86(8):813-8.

View in: PubMed
Collins HL, Sparks CE, Sparks JD. B48 is preferentially translated over B100 in cells with increased endogenous apo B mRNA. Biochem Biophys Res Commun. 2000 Jul 14; 273(3):1156-60.

View in: PubMed
Kalaria VG, Zareba W, Moss AJ, Pancio G, Marder VJ, Morrissey JH, Weiss HJ, Sparks CE, Greenberg H, Dwyer E, Goldstein R, Watelet LF. Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. The THROMBO Investigators. Am J Cardiol. 2000 Jun 15; 85(12):1401-8.

View in: PubMed
Corsetti JP, Sparks JD, Peterson RG, Smith RL, Sparks CE. Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis. 2000 Feb; 148(2):231-41.

View in: PubMed
Sowden MP, Collins HL, Smith HC, Garrow TA, Sparks JD, Sparks CE. Apolipoprotein B mRNA and lipoprotein secretion are increased in McArdle RH-7777 cells by expression of betaine-homocysteine S-methyltransferase. Biochem J. 1999 Aug 1; 341 ( Pt 3):639-45.

View in: PubMed
Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM, Arora R, Marcus FI, Watelet LF, Case RB. Thrombogenic factors and recurrent coronary events. Circulation. 1999 May 18; 99(19):2517-22.

View in: PubMed
Van Mater D, Sowden MP, Cianci J, Sparks JD, Sparks CE, Ballatori N, Smith HC. Ethanol increases apolipoprotein B mRNA editing in rat primary hepatocytes and McArdle cells. Biochem Biophys Res Commun. 1998 Nov 18; 252(2):334-9.

View in: PubMed
Sparks JD, Phung TL, Bolognino M, Cianci J, Khurana R, Peterson RG, Sowden MP, Corsetti JP, Sparks CE. Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia. Metabolism. 1998 Nov; 47(11):1315-24.

View in: PubMed
Moyer MP, Tracy RP, Tracy PB, van't Veer C, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol. 1998 Mar; 18(3):458-65.

View in: PubMed
Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD. Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J Biol Chem. 1997 Dec 5; 272(49):30693-702.

View in: PubMed
Phung TL, Mooney RA, Kulas DT, Sparks CE, Sparks JD. Suppression of the protein tyrosine phosphatase LAR reduces apolipoprotein B secretion by McA-RH7777 rat hepatoma cells. Biochem Biophys Res Commun. 1997 Aug 18; 237(2):367-71.

View in: PubMed
Sparks JD, Collins HL, Sabio I, Sowden MP, Smith HC, Cianci J, Sparks CE. Effects of fatty acids on apolipoprotein B secretion by McArdle RH-7777 rat hepatoma cells. Biochim Biophys Acta. 1997 Jul 12; 1347(1):51-61.

View in: PubMed
Phung TL, Sowden MP, Sparks JD, Sparks CE, Smith HC. Regulation of hepatic apolipoprotein B RNA editing in the genetically obese Zucker rat. Metabolism. 1996 Sep; 45(9):1056-8.

View in: PubMed
Schock D, Kuo SR, Steinburg MF, Bolognino M, Sparks JD, Sparks CE, Smith HC. An auxiliary factor containing a 240-kDa protein complex is involved in apolipoprotein B RNA editing. Proc Natl Acad Sci U S A. 1996 Feb 6; 93(3):1097-102.

View in: PubMed
Sparks JD, Phung TL, Bolognino M, Sparks CE. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem J. 1996 Jan 15; 313 ( Pt 2):567-74.

View in: PubMed
Sparks JD, Sparks CE. Chromatographic method for isolation and quantification of apolipoproteins B-100 and B-48. Methods Enzymol. 1996; 263:104-20.

View in: PubMed
Sparks JD, Sparks CE. Obese Zucker (fa/fa) rats are resistant to insulin's inhibitory effect on hepatic apo B secretion. Biochem Biophys Res Commun. 1994 Nov 30; 205(1):417-22.

View in: PubMed
Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta. 1994 Nov 17; 1215(1-2):9-32.

View in: PubMed
Sparks JD, Corsetti JP, Sparks CE. Liver regrowth and apolipoprotein B secretion by rat hepatocytes following partial hepatectomy. Metabolism. 1994 Jun; 43(6):681-90.

View in: PubMed
Björnsson OG, Sparks JD, Sparks CE, Gibbons GF. Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP-dependent protein kinases. Eur J Clin Invest. 1994 Feb; 24(2):137-48.

View in: PubMed
Harris SG, Sabio I, Mayer E, Steinberg MF, Backus JW, Sparks JD, Sparks CE, Smith HC. Extract-specific heterogeneity in high-order complexes containing apolipoprotein B mRNA editing activity and RNA-binding proteins. J Biol Chem. 1993 Apr 5; 268(10):7382-92.

View in: PubMed
Corsetti JP, Sparks JD, Sikora B, Sparks CE. Cellular heterogeneity in binding and uptake of low-density lipoprotein in primary rat hepatocytes. Hepatology. 1993 Apr; 17(4):645-50.

View in: PubMed
Gibbons GF, Bartlett SM, Sparks CE, Sparks JD. Extracellular fatty acids are not utilized directly for the synthesis of very-low-density lipoprotein in primary cultures of rat hepatocytes. Biochem J. 1992 Nov 1; 287 ( Pt 3):749-53.

View in: PubMed
Björnsson OG, Sparks JD, Sparks CE, Gibbons GF. Prostaglandins suppress VLDL secretion in primary rat hepatocyte cultures: relationships to hepatic calcium metabolism. J Lipid Res. 1992 Jul; 33(7):1017-27.

View in: PubMed
Corsetti JP, Way BA, Sparks CE, Sparks JD. Immunolocalization, quantitation and cellular heterogeneity of apolipoprotein B in rat hepatocytes. Hepatology. 1992 Jun; 15(6):1117-24.

View in: PubMed
Sparks JD, Zolfaghari R, Sparks CE, Smith HC, Fisher EA. Impaired hepatic apolipoprotein B and E translation in streptozotocin diabetic rats. J Clin Invest. 1992 May; 89(5):1418-30.

View in: PubMed
Björnsson OG, Duerden JM, Bartlett SM, Sparks JD, Sparks CE, Gibbons GF. The role of pancreatic hormones in the regulation of lipid storage, oxidation and secretion in primary cultures of rat hepatocytes. Short- and long-term effects. Biochem J. 1992 Jan 15; 281 ( Pt 2):381-6.

View in: PubMed
Corsetti JP, Sterry JA, Sparks JD, Sparks CE, Weintraub M. Effect of weight loss on serum lipoprotein(a) concentrations in an obese population. Clin Chem. 1991 Jul; 37(7):1191-5.

View in: PubMed
Corsetti JP, Weidner CH, Cianci J, Sparks CE. The labeling of lipoproteins for studies of cellular binding with a fluorescent lipophilic dye. Anal Biochem. 1991 May 15; 195(1):122-8.

View in: PubMed
Smith HC, Kuo SR, Backus JW, Harris SG, Sparks CE, Sparks JD. In vitro apolipoprotein B mRNA editing: identification of a 27S editing complex. Proc Natl Acad Sci U S A. 1991 Feb 15; 88(4):1489-93.

View in: PubMed
Backus JW, Eagleton MJ, Harris SG, Sparks CE, Sparks JD, Smith HC. Quantitation of endogenous liver apolipoprotein B mRNA editing. Biochem Biophys Res Commun. 1990 Jul 31; 170(2):513-8.

View in: PubMed
Sparks JD, Sparks CE. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem. 1990 May 25; 265(15):8854-62.

View in: PubMed
Greenland P, Bowley NL, Meiklejohn B, Doane KL, Sparks CE. Blood cholesterol concentration: fingerstick plasma vs venous serum sampling. Clin Chem. 1990 Apr; 36(4):628-30.

View in: PubMed
Greenland P, Bowley NL, French CA, Meiklejohn B, Gagliano S, Sparks CE. Precision and accuracy of a portable blood analyzer system during cholesterol screening. Am J Public Health. 1990 Feb; 80(2):181-4.

View in: PubMed
Kwong TC, Sparks JD, Pryce DJ, Cianci JF, Sparks CE. Inhibition of apolipoprotein B net synthesis and secretion from cultured rat hepatocytes by the calcium-channel blocker diltiazem. Biochem J. 1989 Oct 15; 263(2):411-5.

View in: PubMed
Sparks JD, Sparks CE, Miller LL. Insulin effects on apolipoprotein B production by normal, diabetic and treated-diabetic rat liver and cultured rat hepatocytes. Biochem J. 1989 Jul 1; 261(1):83-8.

View in: PubMed
Jackson TK, Salhanick AI, Sparks JD, Sparks CE, Bolognino M, Amatruda JM. Insulin-mimetic effects of vanadate in primary cultures of rat hepatocytes. Diabetes. 1988 Sep; 37(9):1234-40.

View in: PubMed
Sparks JD, Sparks CE, Bolognino M, Roncone AM, Jackson TK, Amatruda JM. Effects of nonketotic streptozotocin diabetes on apolipoprotein B synthesis and secretion by primary cultures of rat hepatocytes. J Clin Invest. 1988 Jul; 82(1):37-43.

View in: PubMed
Sparks JD, Sparks CE, Roncone AM, Amatruda JM. Secretion of high and low molecular weight phosphorylated apolipoprotein B by hepatocytes from control and diabetic rats. Phosphorylation of APO BH and APO BL. J Biol Chem. 1988 Apr 15; 263(11):5001-4.

View in: PubMed
Tetrault GA, Meiklejohn BA, Sparks CE. Clinical utility of Ektachem-determined bilirubin fractions for classifying adult inpatients. Clin Chem. 1987 Sep; 33(9):1662-4.

View in: PubMed
Sparks CE, Sparks JD, Bolognino M, Salhanick A, Strumph PS, Amatruda JM. Insulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytes. Metabolism. 1986 Dec; 35(12):1128-36.

View in: PubMed
Sparks JD, Bolognino M, Trax PA, Sparks CE. The production and utility of monoclonal antibodies to rat apolipoprotein B lipoproteins. Atherosclerosis. 1986 Sep; 61(3):205-11.

View in: PubMed
Sparks JD, Sparks CE, Kritchevsky D. Hypercholesterolemia and aortic glycosaminoglycans of rabbits fed semi-purified diets containing sucrose and lactose. Atherosclerosis. 1986 May; 60(2):183-96.

View in: PubMed
Shah NM, Eskin BA, Krouse TB, Sparks CE. Iodoprotein formation by rat mammary glands during pregnancy and early postpartum period. Proc Soc Exp Biol Med. 1986 Mar; 181(3):443-9.

View in: PubMed
Kwong TC, Sparks JD, Sparks CE. Lipoprotein and protein binding of the calcium channel blocker diltiazem. Proc Soc Exp Biol Med. 1985 Feb; 178(2):313-6.

View in: PubMed
Sparks JD, Sparks CE. Apolipoprotein B and lipoprotein metabolism. Adv Lipid Res. 1985; 21:1-46.

View in: PubMed
Garber DW, Gottlieb BA, Marsh JB, Sparks CE. Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest. 1984 Oct; 74(4):1375-83.

View in: PubMed
Krebs KE, Phillips MC, Sparks CE. A comparison of the surface activities of rat plasma apolipoproteins C-II, C-III-0, C-III-3. Biochim Biophys Acta. 1983 May 16; 751(3):470-3.

View in: PubMed
Sparks CE, Rader DJ, Marsh JB. Metabolism of two forms of apolipoprotein B of VLDL by rat liver. J Lipid Res. 1983 Feb; 24(2):156-66.

View in: PubMed
Marsh JB, Sparks CE. The effect of fasting on the secretion of lipoproteins and two forms of apo B by perfused rat liver. Proc Soc Exp Biol Med. 1982 Jun; 170(2):178-81.

View in: PubMed
Rash JM, Rothblat GH, Sparks CE. Lipoprotein apolipoprotein synthesis by human hepatoma cells in culture. Biochim Biophys Acta. 1981 Nov 23; 666(2):294-8.

View in: PubMed
Sparks CE, Hnatiuk O, Marsh JB. Hepatic and intestinal contribution of two forms of apolipoprotein B to plasma lipoprotein fractions in the rat. Can J Biochem. 1981 Aug; 59(8):693-9.

View in: PubMed
Sparks CE, Tennenberg SD, Marsh JB. Catabolism of the apolipoproteins of HDL in control and nephrotic rats. Biochim Biophys Acta. 1981 Jul 24; 665(1):8-12.

View in: PubMed
Sparks CE, Tennenberg SD, Marsh JB. Catabolism of apoprotein A-1 of HDL in normal and nephrotic rats. Metabolism. 1981 Apr; 30(4):354-8.

View in: PubMed
Sparks CE, Marsh JB. Metabolic heterogeneity of apolipoprotein B in the rat. J Lipid Res. 1981 Mar; 22(3):519-27.

View in: PubMed
Sparks CE, Marsh JB. Analysis of lipoprotein apoproteins by SDS-gel filtration column chromatography. J Lipid Res. 1981 Mar; 22(3):514-8.

View in: PubMed
Marsh JB, Sparks CE. Hepatic secretion of lipoproteins in the rat and the effect of experimental nephrosis. J Clin Invest. 1979 Nov; 64(5):1229-37.

View in: PubMed
Marsh JB, Sparks CE. Lipoproteins in experimental nephrosis: plasma levels and composition. Metabolism. 1979 Oct; 28(10):1040-5.

View in: PubMed
Capuzzi DM, Sparks CE, DeHoff JL. Effect of residual enzymes on degradation of radioiodinated VLDL by collagenase-dispersed hepatocytes. Biochem Biophys Res Commun. 1979 Sep 27; 90(2):587-95.

View in: PubMed
Sparks CE, Dehoff JL, Capuzzi DM, Pietra G, Marsh JB. Proteolysis of very low density lipoprotein in perfused lung. Biochim Biophys Acta. 1978 Apr 28; 529(1):123-30.

View in: PubMed
Pietra GG, Spagnoli LG, Capuzzi DM, Sparks CE, Fishman AP, Marsh JB. Metabolism of 125I-labeled lipoproteins by the isolated rat lung. J Cell Biol. 1976 Jul; 70(1):33-46.

View in: PubMed
BAGLIONI C, SPARKS CE. A STUDY OF HEMOGLOBIN DIFFERENTIATION IN RANA CATESBEIANA. Dev Biol. 1963 Dec; 47:272-85.

View in: PubMed
BEUREN A, SPARKS C, BING RJ. Metabolic studies on the arrested and fibrillating perfused heart. Am J Cardiol. 1958 Jan; 1(1):103-12.

View in: PubMed